Evidence map›Paper›PMID 42375347›Full record

ReviewFrontiers in immunology2026

Ketone bodies in kidney diseases: novel insights.

Wenni Dai, Weiying Zhang, Hao Li, Yang Gao, Li Xiao, Yinyin Chen, Liyu He

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wenni Dai *Department of Nephrology, Hunan Key Lab of Kidney Disease and Blood Purification, and National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Weiying Zhang *Department of Nephrology, Hunan Key Lab of Kidney Disease and Blood Purification, and National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hao LiDepartment of Nephrology, Hunan Key Lab of Kidney Disease and Blood Purification, and National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yang GaoDepartment of Nephrology, Hunan Key Lab of Kidney Disease and Blood Purification, and National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Li XiaoDepartment of Nephrology, Hunan Key Lab of Kidney Disease and Blood Purification, and National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Yinyin ChenDepartment of Nephrology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, Hunan, China.
Liyu HeDepartment of Nephrology, Hunan Key Lab of Kidney Disease and Blood Purification, and National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ketone bodies (KBs) are important energy fuels and play complex roles in the occurrence and development of diseases by regulating metabolism, inflammation, and multi-organ cellular crosstalk. The high mortality and morbidity of kidney diseases is an urgent global public health problem. The pathogenesis of kidney diseases is complex, with metabolic disorders underlying. Ketone body metabolism has recently become a hot spot, and ketogenic diets (KDs), sodium-glucose cotransporter 2 inhibitors (SGLT2i) along with exogenous ketone body supplements have drawn much attention for their role in treating obesity and type 2 diabetes. Therefore, it is essential to clarify the effects of KBs on kidney diseases to understand the occurrence and development of kidney diseases correctly and guide clinical treatment. This review aims to summarize the current findings on the impact of ketone body metabolism, KDs, SGLT2i and exogenous ketone body supplements on kidney diseases.

Indexed as

Ketone BodiesKidney DiseasesAnimalsDiet, KetogenicHumansKidneySodium-Glucose Transporter 2 InhibitorsKetone BodiesSodium-Glucose Transporter 2 Inhibitorsexogenous ketone supplementHMGCS2ketogenic dietketone body metabolismSGLT2 inhibitor

Identifiers

PMID42375347
PMCPMC13310786

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.